Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with 44m/44Sc and experimental evidence of the feasibility of an in vivo PET generator

Nuclear Medicine and Biology

Volumn 41, Issue S, 2014, Pages

  Huclier Markai, S ^a,b   Kerdjoudj, R ^a   Alliot, C ^a,b   Bonraisin, A C ^b   Michel, N ^b   Haddad, F ^a,b   Barbet, J ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b ARRONAX GIP   (France)

Author keywords

DOTATATE; In vivo generator; PET

Indexed keywords

CONTRAST MEDIUM; PENTETIC ACID; RADIOISOTOPE; SCANDIUM TETRAXETAN SC 44 COMPLEX; SCANDIUM TETRAXETAN SC 44M COMPLEX; SCANDIUM TETRAXETAN [3 TYROSINE, 8 THREONINE]OCTREOTIDE COMPLEX SC 44; SCANDIUM TETRAXETAN [3 TYROSINE, 8 THREONINE]OCTREOTIDE COMPLEX SC 44M; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; OCTREOTIDE; SCANDIUM; SINGLE HETEROCYCLIC RINGS;

ADSORPTION KINETICS; ARTICLE; CHEMICAL PARAMETERS; COMPLEX FORMATION; CONTROLLED STUDY; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; EXPERIMENTAL STUDY; FEASIBILITY STUDY; GAMMA RADIATION; HYDROPHOBIC INTERACTION; IN VIVO STUDY; ISOTOPE LABELING; METAL TO LIGAND RATIO; MOLECULAR INTERACTION; NONHUMAN; PH; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; RADIOISOTOPE DECAY; RAT; TEMPERATURE DEPENDENCE; TIME OF FLIGHT MASS SPECTROMETRY; VALIDITY; CHEMISTRY; CYCLOTRON; DEVICES; DIAGNOSTIC USE; PROCEDURES;

CYCLOTRONS; DRUG STABILITY; FEASIBILITY STUDIES; HETEROCYCLIC COMPOUNDS, 1-RING; ISOTOPE LABELING; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; SCANDIUM;

EID: 84899116967     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.11.004     Document Type: Article

References (39)

1. Bender J.M., Dworkin I. Iodine-131 as an oncologic agent. J Nucl Sci Technol 1993, 21:140-150.
2. 131I]-MIBG therapy for malignant pheochromocytoma. Nucl Med Commun 1991, 12:257-259.
3. 131I]-MIBG. Nucl Med Commun 1989, 10:225-228.
4. Roesch F., Baum R.P. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans 2011 Jun 21, 40(23):6104-6111.
5. Baum R.P., Kulkarni H.R. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - the Bad Berka experience. Theranostics 2012, 2(5):437-447.
6. Mausner L.F., Kolsky K.L., Joshi V., Srivastava S.C. Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot 1998, 49:285-292.
7. Mausner L.F., Joshi V., Kolsky K.L., Meinken G.E., Mease R.C., Sweet M.P., et al. Evaluation of chelating agents for radioimmunotherapy with scandium-47. J Nucl Med 1995, 36:104-110.
8. Kolsky K.L., Pietrelli L., Mausner L.F., Srivastava S.C. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. J Nucl Med 1995, 32:945-950.
9. 47Sc from titanium targets. Radiochim Acta 2012, 100:457-463.
10. 47Sc-complexes with acyclic polyamino-polycarboxylate ligands. J Radioanal Nucl Chem 2013, 295:1867-1872.
11. 103mRh-recoil considerations. Appl Radiat Isot 2008, 66:1346-1349.
12. 140Nd-DOTA. Radiochim Acta 2007, 95:319-327.
13. 166Ho. Radiochim Acta 2011, 99:1-5.
14. 44Sc radionuclide with liquid xenon as detection medium. Nucl Inst Methods Phys Res A 2007, 571(1-2):142-153.
15. 44Sc-based PET-radiopharmaceuticals. Radiochim Acta 2010, 98:149-156.
16. 44Sc. J Label Compd Radiopharm 2009, 52:S490.
17. 44Sc. Appl Radiat Isot 2012, 70(6):974-979.
18. 44gSc from natural calcium. Appl Radiat Isot 2012, 70(8):1526-1530.
19. natGa-DOTA-TATE. Nucl Med Rev 2011, 14(2):85-89.
20. Majkowska-Pilip A., Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 2011, 105:313-320.
21. Huclier-Markai S., Sabatie A., Ribet S., Kubicek V., Paris M., Vidaud C., et al. Chemical and biological evaluation of scandium(III)-polyaminopolycarboxylate complexes as potential PET agent and radiopharmaceutical. Radiochim Acta 2011, 99:653-662.
22. Moghaddam-Banaem L., Jalilian A.R., Pourjavid M.R., Radfar E., Bahrami-Samani A., Yavari K., et al. Development of a radioscandium immunoconjugate for radioimmunotherapy. Radiochim Acta 2012, 100:215-221.
23. 44m/44Sc generator for potential medical applications: production and chemistry aspects 2013, [Submitted to Appl. Rad., Isot.].
24. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002, 57:841-847.
25. 90Y-labeled DOTA analogues conjugated to B72.3. Nucl Med Biol 2007, 34:493-502.
26. Meyer D., Schaefer M., Bonnemain B. Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge. Invest. Radiol. 1988, 23:S232-S235.
27. Oudkerk M., Sijens P.E., van Beek E.J., Kuijpers T.J. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest. Radiol. 1995, 30:75-78.
28. Frampas E., Maurel M., Remaud-Le Saec P., Mauxion T., Faivre-Chauvet A., Davodeau F., et al. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imag 2011, 38:2153-2164.
29. 18F-Labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 2010, 9:1019-1027.
30. Gold D.A., Goldenberg D.M., Karacay H., Rossy E.A., Chang C.H., Cardillo T.M., et al. A novel bispecific trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008, 68:4819-4826.
31. Green J., Pagel J.M., Pantelias A., Hedin N., Lin Y., Wilbur D.S., et al. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res 2007, 13:5598-5603.
32. Loncin M.F., Desreux J.F., Merciny E. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg Chem 1986, 25:2646-2649.
33. Moi M.K., Meares C.F., DeNardo S.J. The peptide way of macrocyclic bifunctional chelating agents. Synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetracyclododecane-N, N', N", N"', N""-tetraacetic acid, and study of its yttrium (III) complex. J Am Chem Soc 1988, 110:6266-6271.
34. Izatt R., Pawlak K., Bradshaw S.J., Bruening R.L. Thermodynamic and kinetic data for macrocycle interaction with cations, anions, and neutral molecules. Chem Rev 1995, 95:2529-2533.
35. 44Sc-radionuclide generator. J Nucl Med 2010, 51(S2):1467-1473.
36. 103mRh. Appl Radiol Isot 2009, 67:1401-1404.
37. Cole W.C., Denardo S.J., Meares C.F., McCall M.J., Denardo G.L., Epstein A.L., et al. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med 1987, 28(1):83.
38. natGa-DOTA-TATE. Nucl Med Rev 2011, 14(2):85-89.
39. Cutler C.S., Hennekens H., Nebiat S., Huclier-Markai S., Jurisson S.S. Combined radionuclide imaging and therapy. Chem Rev 2013, 113(2):858-883.